Morepen reports Rs 56.4 cr profit while broadening its healthcare platform
Consolidated operating profit was Rs 82.53 cr at a 14.48% margin, while management highlighted capacity utilisation and operating leverage.
Filed 04 Aug 2026, 13:50 IST · MOREPENLAB (MOREPENLAB)
Key takeaways
- Morepen Laboratories reported consolidated net profit of Rs 56.4 cr in Q1FY27 on operating profit of Rs 82.53 cr.
- Operating margin stood at 14.48%, with expenses of Rs 487.59 cr against revenue of Rs 570.13 cr.
- Management said Morepen is expanding from medical devices into a chronic-care health platform.
Q1FY27 earnings were led by operating profit
Morepen Laboratories reported consolidated profit before tax of Rs 74.58 cr and net profit of Rs 56.4 cr. Operating profit of Rs 82.53 cr was higher than pre-tax profit after interest of Rs 4.84 cr and depreciation of Rs 8.35 cr. Other income was Rs 5.24 cr, so pre-tax earnings were primarily operating rather than other-income-led.
A 14.48% margin sets the operating baseline
The quarter's operating margin was 14.48%, based on revenue of Rs 570.13 cr and expenses of Rs 487.59 cr. The tax rate was 24.38%, leaving tax of Rs 18.18 cr against profit before tax of Rs 74.58 cr. With no reported comparison in the release, the key operating read-through is whether the business can sustain this margin while managing its cost base.
Management is repositioning beyond medical devices
The company said it is expanding from medical devices into a chronic-care health platform. Management also identified capacity utilisation, operating leverage and sustainable value creation as priorities in its growth outlook. These themes put the 14.48% operating margin and Rs 570.13 cr revenue base at the centre of the next period's assessment.
Q1FY27 at a glance
Consolidated figures as filed with NSE — filed ahead of third-party databases, not yet independently cross-checked.
| Line item | Q1FY27 |
|---|---|
| Revenue | ₹570 cr |
| Other income | ₹5 cr |
| Expenses | ₹488 cr |
| Operating profit | ₹83 cr |
| Operating margin (%) | 14.48% |
| Interest | ₹5 cr |
| Depreciation | ₹8 cr |
| Profit before tax | ₹75 cr |
| Tax | ₹18 cr |
| Net profit | ₹56 cr |
| EPS (₹) | ₹1.03 |
What management said
From the company’s own investor presentation. Each point is checked against the source document before it appears here.
Guidance & outlook
- The company identifies capacity utilisation, operating leverage and sustainable value creation in its growth outlook.
New initiatives
- Morepen is expanding from medical devices into a chronic-care health platform.
What to watch
- Whether operating margin holds at 14.48% as management focuses on capacity utilisation and operating leverage.
- Whether revenue moves above or below the Rs 570.13 cr Q1FY27 base as the chronic-care platform expands.
- Whether other income remains near Rs 5.24 cr, keeping earnings primarily operating-led.